StreetInsider.com News Articles

Form 8-K SANUWAVE Health, Inc. For: Jul 13

Mon, 13 Jul 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260713/26762936.html

Form 8-K SANUWAVE Health, Inc. For: Jul 13

Mon, 13 Jul 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260713/26762936.html

Form 8-K SANUWAVE Health, Inc. For: Jul 13

Mon, 13 Jul 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260713/26762936.html

Sanuwave Q2 2026 revenue tops revised guidance range

Mon, 13 Jul 2026 16:31:09 -0400

Sanuwave Health, Inc. (NASDAQ: SNWV) reported preliminary, unaudited second-quarter 2026 revenue of $9.6 million to $9.8 million, above the high end of its revised guidance range of $8.5 million to $9.5 million, according to a press release.

The preliminary figures represent a decrease of approximately 3% to 5% compared with revenue of $10.1 million in the second quarter of 2025.

CEO Morgan Frank attributed capital sales weakness to stress in the company's customer base and the presence of used Ultramist systems in the secondary market. "The business played out largely as we had forecast with capital sales facing headwinds from stress in

Sanuwave Q2 2026 revenue tops revised guidance range

Mon, 13 Jul 2026 16:31:09 -0400

The preliminary figures represent a decrease of approximately 3% to 5% compared with revenue of $10.1 million in the second quarter of 2025.

Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance

Mon, 13 Jul 2026 16:30:00 -0400

Sanuwave announces preliminary, unaudited revenues of $9.6 million to $9.8 million for the second quarter ended June 30, 2026, above the high end of the Company’s revised guidance of $8.5 to $9.5 million

EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $9.6 to $9.8 million, above the high end of the revised guidance range of $8.5 to $9.5 million

Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance

Mon, 13 Jul 2026 16:30:00 -0400

Form 4 SANUWAVE Health, Inc. For: Jun 30 Filed by: Blizard Jeffrey

Thu, 02 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260702/26727897.html

Form 4 SANUWAVE Health, Inc. For: Jun 30 Filed by: Blizard Jeffrey

Thu, 02 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260702/26727897.html

Form 4 SANUWAVE Health, Inc. For: Jun 30 Filed by: Bazar Gregory Matthew

Thu, 02 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260702/26727862.html

Form 4 SANUWAVE Health, Inc. For: Jun 30 Filed by: Bazar Gregory Matthew

Thu, 02 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260702/26727862.html

Form 4 SANUWAVE Health, Inc. For: Jun 30 Filed by: Miller Ian D.

Thu, 02 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260702/26727883.html

Form 4 SANUWAVE Health, Inc. For: Jun 30 Filed by: Miller Ian D.

Thu, 02 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260702/26727883.html

Form 4 SANUWAVE Health, Inc. For: Jun 30 Filed by: Tyler James

Thu, 02 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260702/26727839.html

Form 4 SANUWAVE Health, Inc. For: Jun 30 Filed by: Tyler James

Thu, 02 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260702/26727839.html

Form 4 SANUWAVE Health, Inc. For: Jun 30 Filed by: FRANK MORGAN C.

Thu, 02 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260702/26727823.html

Form 4 SANUWAVE Health, Inc. For: Jun 30 Filed by: FRANK MORGAN C.

Thu, 02 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260702/26727823.html

Form 8-K SANUWAVE Health, Inc. For: Jun 16

Tue, 16 Jun 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26650856.html

Form 8-K SANUWAVE Health, Inc. For: Jun 16

Tue, 16 Jun 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26650856.html

Form 8-K SANUWAVE Health, Inc. For: Jun 16

Tue, 16 Jun 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26650856.html

Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure

Tue, 16 Jun 2026 08:00:46 -0400

Sanuwave Health, Inc. (NASDAQ: SNWV) revised its second-quarter 2026 revenue guidance to a range of $8.5 million to $9.5 million, below the outlook the company provided during its first-quarter earnings call on May 13, 2026.

CEO Morgan Frank attributed the revision to deteriorating conditions in the capital equipment market for the company's Ultramist system. Frank said that while March and April had shown signs of improvement, May and early June brought a reversal of those trends.

Frank cited widespread clawbacks of CMS reimbursement for skin substitutes and allograft usage as a key factor driving wound care practices out of business. He said

Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure

Tue, 16 Jun 2026 08:00:46 -0400

Frank cited widespread clawbacks of CMS reimbursement for skin substitutes and allograft usage as a key factor driving wound care practices out of business. He said

Sanuwave Health Updates Second Quarter 2026 Guidance

Tue, 16 Jun 2026 08:00:00 -0400

Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million

Company on pace for record unit sales of applicators in Q2

Market disruption impacting Ultramist system sales

EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $8.5 to $9.5 million, below the guidance provided on the Q1 earnings call on May 13

Sanuwave Health Updates Second Quarter 2026 Guidance

Tue, 16 Jun 2026 08:00:00 -0400

Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million

Company on pace for record unit sales of applicators in Q2

Market disruption impacting Ultramist system sales

Form 8-K SANUWAVE Health, Inc. For: Jun 11

Mon, 15 Jun 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260615/26648721.html